Skip to main content

Table 4 Comparison of the age characteristics of the epilepsy cases in 1991–1992 and 2017

From: Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon

 

1991–1992

2017

SCE

SCE

P

PWE

P

Age (years), median (IQR)

16 (13–21)

26 (20–34)

<0.001

24 (20–32)

<0.001

Age group

 < 10 years, n (%)

8 (9.5)

3 (2.7)

 

1 (1.2)

 

 10–19 years, n (%)

49 (58.3)

23 (20.5)

 

18 (22.2)

 

 20–29 years, n (%)

21 (25.0)

44 (39.3)

 

34 (42.0)

 

 ≥ 30 years, n (%)

6 (7.1)

42 (37.5)

 

28 (34.6)

 

Crude age-specific prevalencea

  

<0.001

 

<0.001

 < 10 years, (%)

2.5

0.4

 

0.1

 

 10–19 years, (%)

22.3

4.9

 

3.8

 

 20–29 years, (%)

16.3

11.6

 

9.0

 

 ≥ 30 years, (%)

1.6

6.0

 

4.0

 

Age at onset (years), median (IQR)

12 (8–15)b

na

 

12 (10–14)c

0.294

Age group at onset

 < 10 years, n (%)

21 (25.0)

  

19 (24.4)

 

 10–19 years, n (%)

49 (58.3)

  

57 (73.1)

 

 20–29 years, n (%)

5 (6.0)

  

1 (1.3)

 

 ≥ 30 years, n (%)

1 (1.2)

  

1 (1.3)

 

Years since onset of epilepsy, median (IQR)

5 (2.0–7.5)b

na

 

12.5 (7–21)b

<0.001

  1. aEstimated number of people per age group (< 10, 10–19, 20–29 and ≥ 30 years) were obtained by applying the age structure of districts from the 1987 census
  2. b8 missing data
  3. Abbreviation: na, not available